Sanofi has launched the first self-monitoring device that provides estimates of the HbA1c value, a key indicator for long-term glucose control.
The company claims its MyStar Extra® blood glucose monitoring device may help people with diabetes better understand the meaning of their test results in the context of overall treatment goals.
Several extra features of the device may help people with diabetes stay motivated and engaged in managing their insulin therapy, Sanofi said.
For the full story, click here.